Pentosan polysulfate as a prophylactic and therapeutic agent against prion disease

IDrugs

Volumn 6, Issue 5, 2003, Pages 470-478

  Dealler, Stephen ^a   Rainov, Nikolai G ^b  

^a ROYAL LANCASTER INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Creutzfeldt Jakob disease; Glycosaminoglycan; Pentosan polysulfate; Prion

Indexed keywords

ANTICOAGULANT AGENT; ANTIVIRUS AGENT; BRADYKININ B2 RECEPTOR AGONIST; CARRAGEENAN; CHONDROITIN SULFATE; CONGO RED; DAPSONE; DEXTRAN; DEXTRAN SULFATE; DIETHYLAMINOETHYLDEXTRAN; GLYCOSAMINOGLYCAN; HEPARAN; HEPARAN SULFATE; HEPARIN; LOBRADIMIL; MANNITOL; PENTOSAN POLYSULFATE; POLYANION; PRION PROTEIN; SULFATED COLOMINIC ACID; SULFATED PHTHALOCYANIN DERIVATIVE; SULFATED PORPHYRIN DERIVATIVE; SULFONATED POLYGLYCOSIDE DERIVATIVE; SURAMIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; BLOOD BRAIN BARRIER; BLOOD TRANSFUSION; BRAIN EDEMA; CALCIUM OXALATE STONE; CELL CULTURE; CELL DAMAGE; CELL LEVEL; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ULCER; LYSOSOME STORAGE DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PRION; PRION DISEASE; PROPHYLAXIS; PROTEIN METABOLISM; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; REVIEW; SCRAPIE; SIDE EFFECT; THROMBOCYTOPENIA;

ANIMALS; HUMANS; PENTOSAN SULFURIC POLYESTER; PRION DISEASES;

EID: 0038206890     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Harris DA: Biosynthesis and cellular processing of the prion protein. Adv Protein Chem (2001) 57:203-228. The latest insight into the cellular manufacture of prions.
2. Brown DR: Copper and prion disease. Brain Res Bull (2001) 55:165-173.
3. Brown DR, Wong BS, Hafiz F, Clive C, Haswell SJ, Jones IM: Normal prion protein has an activity like that of superoxide dismutase. Biochem J (1999) 344:1-5.
4. C. Philos Trans R Soc Lond Biol (1994) 343:431-433.
5. Vorberg I, Priola SA: Molecular basis of scrapie strain glycoform variation. J Biol Chem (2002) 277:36775-36781.
6. Huang Z, Prusiner SB, Cohen FE: Scrapie prions: A three-dimensional model of an infectious fragment. Folding Des (1996) 1:13-19.
7. Weissmann C, Bueler H, Fischer M, Sailer A, Aguzzi A, Aguet M. PrP-deficient mice are resistant to scrapie. Ann NY Acad Sci (1994) 724:235-240.
8. Aguzzi A, Klein MA, Musahl C, Raeber AJ, Blattler T, Hegyi I, Frigg R, Brandner S: Use of brain grafts to study the pathogenesis of prion diseases. Essays Biochemistry (1998) 33:133-147.
9. Rezaie P, Lantos PL: Microglia and the pathogenesis of spongiform encephalopathies. Brain Res Brain Res Rev (2001) 35:55-72.
10. Hadlow WJ: Reflections on the transmissible spongiform encephalopathies. Vet Pathol (1999) 36:523-529.
11. Brown KL, Stewart K, Ritchie D, Fraser H, Morrison WI, Bruce ME: Follicular dendritic cells in scrapie pathogenesis. Arch Virol Suppl (2000) 16:13-21.
12. Beringue V, Demoy M, Lasmezas CI, Gouritin B, Weingarten C, Deslys JP, Andreux JP, Couvreur P, Dormont D: Role of spleen macrophages in the clearance of scrapie agent early in pathogenesis. J Pathol (2000) 190:495-502.
13. Casaccia P, Ladogana A, Xi YG, Pocchiari M: Levels of infectivity in the blood throughout the incubation period of hamsters peripherally injected with scrapie. Arch Virol (1989) 108:145-149.
14. Bruce ME, Fraser H: Scrapie strain variation and its implications. Curr Top Microbiol Immunol (1991) 172:125-138.
15. McBride PA, Schulz-Schaeffer WJ, Donaldson M, Bruce M, Diringer H, Kretzschmar HA, Beekes M: Early spread of scrapie from the gastrointestinal tract to the central nervous system involves autonomic fibers of the splanchnic and vagus nerves. J Virol (2001) 75:9320-9327.
16. Huang FP, Farquhar CF, Mabbott NA, Bruce ME, MacPherson GG. Migrating intestinal dendritic cells transport PrP(Sc) from the gut. J Gen Virol (2002) 83:267-271.
17. Kimberlin RH, Walker CA: Pathogenesis of experimental scrapie. Ciba Found Symp (1988) 135:37-62.
18. Ehlers B, Rudolf R, Diringer H: The reticuloendothelial system in scrapie pathogenesis. J Gen Virol (1984) 65:423-428.
19. Ehlers B, Diringer H: Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J Gen Virol (1984) 65:1325-1330.
20. Farquhar C, Dickinson A: Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before of after infection. J Gen Virol (1986) 67:463-473.
21. Kimberlin R, Walker CA: Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions. Antimicrob Agents Chemother (1986) 30:409-413.
22. Diringer H, Ehlers B: Chemoprophylaxis of scrapie in mice. J Gen Virol (1991) 72:457-460. The most clear demonstration of PPS activity as a prophylactic agent.
23. Ladogana A, Casaccia P, Ingrosso L, Cibati M, Salvatore M, Xi YG, Masullo C, Pocchiari M: Sulphate polyanions prolong the incubation period of scrapie infected hamsters. J Gen Virol (1992) 73:661-665.
24. Farquhar C, Dickinson A, Bruce M: Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet (1999) 353:117.
25. Farquhar C, Barclay R, Pepper D, Brown K, Ritchie D, Burns R, Turner M, Bruce M: Investigation of pentosan polysulphate as a potential prophylactic agent against transmission of nvCJD by blood and blood products. Policy Research Programme, Department of Health, UK. http://www.doh.gov.uk/cjd/pentosan.htm
26. Farquhar CF, McConnell I, Graham J, Cumming S, Prescott RJ, Boyle A, Barclay GR, Pepper DS, Turner ML, Bruce ME: Pentosan polysulphate has prophylactic potential for transmissible spongiform encephalopathies. New Perspectives for Prion Therapeutics Conference, Paris, France, December (2002) (2002):Abs 0-06.
27. Doh-Ura K, Ishikawa K, Murakami-Kubo I, Sasaki K, Mohri S, Race R, Iwaki T: Intraventricular infusion of pentosan polysulfate as an immediately applicable treatment for prion diseases. New Perspectives for Prion Therapeutics Conference, Paris, France, December (2002) (2002) Abs 0-07. First report of the efficacy of PPS in rodents infected with TSE.
28. Todd N, Dealler S, Rainov N: The treatment of vCJD with pentosan polysulphate. Lancet (2003): manuscript submitted.
29. Caughey B, Race RE: Potent inhibition of scrapie associated PrP accumulation by Congo Red. J Neurochem (1992) 59:768-771.
30. Caughey B, Raymond GJ: Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J Virol (1993) 67:643-650. The first demonstration of PPS activity in vitro.
31. Caughey B: Protease-resistant PrP accumulation and scrapie agent replication: A role for sulphated glycosoaminoglycans? Biochem Soc Trans (1994) 22:163-167.
32. Caughey B, Brown K, Raymond GJ, Katzenstein GE, Thresher W: Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosoaminoglycans and Congo Red. J Virol (1994) 68:2135-2141.
33. Sc and delays onset of prion disease. EMBO J (2001) 20:3957-3966.
34. Manuelidis L, Fritch W, Zaitsev I: Dapsone to delay symptoms in Creutzfeldt-Jakob disease. Lancet (1998) 352:456.
35. Guenther K, Deacon RM, Perry VH, Rawlins JN: Early behavioural changes in scrapie-affected mice and the influence of dapsone. Eur J Neurosci (2001) 14:401-409.
36. Priola SA, Raines A, Caughey WS: Porphyrin and phthalocyanine antiscrapie compounds. Science (2000) 287:1503-1506.
37. Priola SA, Caughey B, Caughey W: Novel therapeutic uses for prophyrins and phthalocyanines in the transmissible spongiform encephalopathies. Curr Opin Microbiol (1999) 2:563-566.
38. Gabizon R, Meiner Z, Halimi M, Ben-Sasson SA: Heparin-like molecules bind differentially to prion-proteins and change their intracellular metabolic fate. J Cell Physiol (1993) 157:319-325.
39. C in cultured cells. J Biol Chem (1995) 270:30221-30229.
40. Sc and HIV-1 gp120-induced neuronal cell death by sulfated colominic acid. J Neurovirol (1999) 5:289-299.
41. Brimacombe DB, Bennett AD, Wusteman FS, Gill AC, Dann JC, Bostock CJ: Characterization and polyanion-binding properties of purified recombinant prion protein. Biochem J (1999) 342:605-613.
42. Dealler S, Barclay GR: Pentosan polysulfate is concentrated inside leucocytes to levels previously shown to inhibit prion production. Characterization and Diagnosis of Prion Disease in Animals and Man Symposium, Tubingen, Germany (1999).
43. Conrad HE (Ed): Heparin-Binding Proteins. Academic Press, San Diego, CA, USA (1998).
44. Sc-dependent cell-free formation of protease-resistant prion protein. EMBO J (2001) 20:377-386.
45. Leveugle B, Scanameo A, Ding W, Fillit H: Binding of heparan sulfate glycosaminoglycan to β-amyloid peptide: Inhibition by potentially therapeutic polysulfated compounds. Neuroreport (1994) 5:1389-1392.
46. Tan SY, Pepys MB: Amyloidosis. Histopathology (1994) 25:403-414.
47. McBride PA, Wilson MI, Eikelenboom P, Tunstall A, Bruce ME: Heparan sulfate proteoglycan is associated with amyloid plaques and neuroanatomically targeted PrP pathology throughout the incubation period of scrapie-infected mice. Exp Neurol (1998) 149:447-454.
48. Ailles L, Kisilevsky R, Young ID: Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidogenesis. Lab Invest (1993) 69:443-448.
49. Kisilevsky R, Fraser PE: Aβ amyloidogenesis: Unique, or variation on a systemic theme? Crit Rev Biochem Mol Biol (1997) 32:361-404.
50. Inoue S, Hultin PG, Szarek WA, Kisilevsky R: Effect of poly(vinylsulfonate) on murine AA amyloid: A high-resolution ultrastructural study. Lab Invest (1996) 74:1081-1090.
51. Castillo GM, Ngo C, Cummings J, Wight TN, Show AD: Perlecan binds to the β-amyloid proteins (Aβ) of Alzheimer's disease, accelerates Aβ fibril formation and maintains Aβ fibril stability. J Neurochem (1997) 69:2452-2465.
52. Castillo GM, Cummings JA, Yang W, Judge ME, Sheardown MJ, Rimvall K, Hansen JB, Snow AD: Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. Diabetes (1998) 47:612-620.
53. Dealler S: Transmissible spongiform encephalopathy (TSE) agents as crystalline forms of the prion protein (PrP) that multiply by allowing normal metabolic forms of PrP to join the crystal. Med Hypotheses (1991) 36:131-134.
54. Liberski PP, Brown P, Xiao SY, Gajdusek DC: The ultrastructural diversity of scrapie-associated fibrils isolated from experimental scrapie and Creutzfeldt-Jakob disease. J Comp Pathol (1991) 105:377-386.
55. Van Rheede T, Smolenaars MM, Madsen O, De Jong WW: Molecular evolution of the mammalian prion protein. Mol Biol Evol (2003) 20:111-121.
56. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L: Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest (1995) 108:258S-275S.
57. MacGregor IR, Dawes J, Pepper DS, Prowse CV, Stocks J: Metabolism of sodium pentosan polysulphate in man measured by a new competitive binding assay for sulphated polysaccharides - Comparison with effects upon anticoagulant activity, lipolysis and platelet α-granule proteins. Thromb Haemost (1985) 53:411-414.
58. MacGregor IR, Dawes J, Paton L, Pepper DS, Prowse CV, Smith M: Metabolism of sodium pentosan polysulphate in man - Catabolism of iodinated derivatives. Thromb Haemost (1984) 51:321-325.
59. Dawes J, Prowse CV, Pepper DS: The measurement of heparin and other therapeutic sulphated polysaccharides in plasma, serum and urine. Thromb Haemost (1985) 54:630-634.
60. Wells XE, Dawes J: Role of the liver and kidney in the desulphation of heparin in vivo. Thromb Haemost (1995) 74:667-672.
61. Dawes J, Pepper DS: Human vascular endothelial cells catabolise exogenous glycosaminoglycans by a novel route. Thromb Haemost (1992) 67:468-472.
62. Krummer M, Kunz K, Bauer R: Absorption, distribution and excretion of tritiated SP54 after parenteral and oral application in eight healthy male volunteers. Final Report SP54 MK/a-37. Labor fur Pharmacokinetik und Biopharmazie, Munich 83, Germany. Available at IVAX UK Ltd, London, UK.
63. Sie P, Albarede JL, Robert M, Bouloux C, Lansen J, Chigot C, Correll S, Thouvenot JP, Boneu B: Tolerance and biological activity of pentosan polysulphate after intramuscular or subcutaneous administration for ten days in human volunteers. Thromb Haemost (1986) 55:86-89.
64. Fellstrom B, Bjorklund U, Danielson BG et al: Pentosan polysulphate (Elmiron): Pharmacokinetics and effect on the urinary inhibition of crystal growth. In: Pathogeneses und Klinik der Harnsteine. Vahlensieck W, Gasser G (Eds), Steinkopff-Verlag, Darmstadt, Germany (1987):340-343.
65. Senthil D, Subha K, Saravanan N, Varalakshmi P: Influence of sodium pentosan polysulphate and certain inhibitors on calcium oxalate crystal growth. Mol Cell Biochem (1996) 156:31-35.
66. Forestier F, Fisher AM, Daffos F, Beguin S Diner H: Absence of transplacental passage of pentosan polysulfate during mid trimester of pregnancy. Thromb Haemost (1986) 56:247-249.
67. Mulholland SG, Hanno P, Parsons CL, Sant GR, Staskin DR: Pentosan polysulfate sodium for therapy of interstitial cystitis: A double-blind placebo-controlled clinical study. Urology (1990) 35:552-558.
68. Tardy-Poncet B, Tardy B, Grelac F, Reynaud J, Mismetti P, Bertrand JC, Guyotat D: Pentosan polysulfate-induced thrombocytopenia and thrombosis. Am J Hematol (1994) 45:252-257.
69. 125]-thrombin with antithrombin III or heparin cofactor II of human plasma. Eur J Drug Metab Pharmacokinet (1995) 20:73-77.
70. Swain SM, Parker B, Wellstein A, Lippman ME, Steakley C, DeLap R: Phase I trial of pentosan polysulfate. Invest New Drugs (1995) 13:55-62.
71. Losonczy H, David M, Nagy I: Effect of pentosan polysulfate on activated partial thromboplastin time, thrombin time, euglobulin clot lysis and on tissue-type plasminogen activator and plasminogen activator inhibitor activities in patients with thromboembolic disease. Semin Thromb Haemost (1991) 17:394-398.
72. Parsons CL, Mulholland SG: Successful therapy of interstitial cystitis with pentosan polysulfate. J Urol (1987) 138:513-516.
73. Grigsby PW, Pilepich MV, Parsons CL: Preliminary results of a phase I/II study of sodium pentosan polysulfate in the treatment of chronic radiation-induced proctitis. Am J Clin Oncol (1990) 13:28-31.
74. Marshall JL, Wellstein A, Rae J, DeLap RJ, Phipps K, Hanfelt J, Yunmbam MK, Sun JX, Duchin KL, Hawkins MJ: Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer. Clin Cancer Res (1997) 3:2347-2354. PPS caused benign bowel ulceration, which healed after drug cessation.
75. Ghosh P: The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Semin Arthritis Rheum (1999) 28:211-267.
76. Nyska A, Nold JB, Johnston JD, Abdo K: Lysosomal-storage disorder induced by elmiron following 90-days gavage administration in rats and mice. Toxicol Pathol (2002) 30:178-187.
77. Elmiron® (pentosan polysulfate sodium): Alza Corp, Palo Alto, CA, USA. http://www.elmiron100.com/info.html
78. c. Neuroreport (2000) 11:3931-3936.
79. Deli MA, Abraham CS, Takahata H, Katamine S, Niwa M: Pentosan polysulfate regulates scavenger receptor-mediated, but not fluid-phase, endocytosis in immortalized cerebral endothelial cells. Cell Mol Neurobiol (2000) 20:731-745.
80. Lee DC, Stenland CJ, Miller JL, Cai K, Ford EK, Gilligan KJ, Hartwell RC, Terry JC, Rubenstein R, Fournel M, Petteway SR Jr: A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion (2001) 41:449-455.
81. Dealler S: Transmissible spongiform encephalopathy. Rev Med Microbiol (1998) 9:135-152.
82. Rapaport SI: Advances in osmotic opening of the blood-brain barrier to enhance CNS chemotherapy. Expert Opin Investig Drugs (2001) 10:1809-1818.
83. Emerich DF, Dean RL, Osborn C, Bartus RT: The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: From concept to clinical evaluation. Clin Pharmcokin (2001) 40:105-123.
84. Shaked GM, Shaked Y, Kariv-Inbal Z, Halimi M, Avraham I, Gabizon R: A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases. J Biol Chem (2001) 276:31479-31482.